BACKGROUND: Women with germline BRCA1 or BRCA2 (BRCA1/BRCA2) mutations are at very high risk of developing breast cancer, including asynchronous contralateral breast cancer (CBC). BRCA1/BRCA2 genes help maintain genome stability and assist in DNA repair. We examined whether the risk of CBC associated with radiation treatment was higher among women with germline BRCA1/BRCA2 mutations than among non-carriers. METHODS: A population-based, nested case-control study was conducted within a cohort of 52,536 survivors of unilateral breast cancer (UBC). Cases were 603 women with CBC and controls were 1199 women with UBC individually matched on age at diagnosis, race, year of first diagnosis and cancer registry. All women were tested for BRCA1 and BRCA2 mutations. Radiation absorbed dose from the initial radiotherapy (RT) to the CBC location within the contralateral breast was reconstructed from measurements in a tissue-equivalent phantom and details available in the therapy records. FINDINGS: Among women treated with radiation, the mean radiation dose was 1.1 Gy (range = 0.02-6.2 Gy). Risk of developing CBC was elevated among women who carried a deleterious BRCA1/BRCA2 mutation (rate ratio, RR = 4.5, confidence interval, CI = 3.0-6.8), and also among those treated with RT (RR = 1.2, CI = 1.0-1.6). However, among mutation carriers, an incremental increase in risk associated with radiation dose was not statistically significant. INTERPRETATION: Multiplicative interaction of RT with mutation status would be reflected by a larger association of RT with CBC among carriers than among non-carriers, but this was not apparent. Accordingly, there was no clear indication that carriers of deleterious BRCA/BRCA2 mutations were more susceptible to the carcinogenic effects of radiation than non-carriers. These findings are reassuring and have important clinical implications for treatment decisions and the clinical management of patients harbouring deleterious BRCA1/BRCA2 mutations. FUNDING: All work associated with this study was supported by the U.S. National Cancer Institute [R01CA097397, U01CA083178].
BACKGROUND:Women with germline BRCA1 or BRCA2 (BRCA1/BRCA2) mutations are at very high risk of developing breast cancer, including asynchronous contralateral breast cancer (CBC). BRCA1/BRCA2 genes help maintain genome stability and assist in DNA repair. We examined whether the risk of CBC associated with radiation treatment was higher among women with germline BRCA1/BRCA2 mutations than among non-carriers. METHODS: A population-based, nested case-control study was conducted within a cohort of 52,536 survivors of unilateral breast cancer (UBC). Cases were 603 women with CBC and controls were 1199 women with UBC individually matched on age at diagnosis, race, year of first diagnosis and cancer registry. All women were tested for BRCA1 and BRCA2 mutations. Radiation absorbed dose from the initial radiotherapy (RT) to the CBC location within the contralateral breast was reconstructed from measurements in a tissue-equivalent phantom and details available in the therapy records. FINDINGS: Among women treated with radiation, the mean radiation dose was 1.1 Gy (range = 0.02-6.2 Gy). Risk of developing CBC was elevated among women who carried a deleterious BRCA1/BRCA2 mutation (rate ratio, RR = 4.5, confidence interval, CI = 3.0-6.8), and also among those treated with RT (RR = 1.2, CI = 1.0-1.6). However, among mutation carriers, an incremental increase in risk associated with radiation dose was not statistically significant. INTERPRETATION: Multiplicative interaction of RT with mutation status would be reflected by a larger association of RT with CBC among carriers than among non-carriers, but this was not apparent. Accordingly, there was no clear indication that carriers of deleterious BRCA/BRCA2 mutations were more susceptible to the carcinogenic effects of radiation than non-carriers. These findings are reassuring and have important clinical implications for treatment decisions and the clinical management of patients harbouring deleterious BRCA1/BRCA2 mutations. FUNDING: All work associated with this study was supported by the U.S. National Cancer Institute [R01CA097397, U01CA083178].
Authors: Lori J Pierce; Albert M Levin; Timothy R Rebbeck; Merav A Ben-David; Eitan Friedman; Lawrence J Solin; Eleanor E Harris; David K Gaffney; Bruce G Haffty; Laura A Dawson; Steven A Narod; Ivo A Olivotto; Andrea Eisen; Timothy J Whelan; Olufunmilayo I Olopade; Claudine Isaacs; Sofia D Merajver; Julia S Wong; Judy E Garber; Barbara L Weber Journal: J Clin Oncol Date: 2006-04-24 Impact factor: 44.544
Authors: Deborah Goldfrank; Shannon Chuai; Jonine L Bernstein; Teresa Ramon Y Cajal; Johanna B Lee; M Carmen Alonso; Orland Diez; Monserrat Baiget; Noah D Kauff; Kenneth Offit; Mark Robson Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-11 Impact factor: 4.254
Authors: Nadine Andrieu; Douglas F Easton; Jenny Chang-Claude; Matti A Rookus; Richard Brohet; Elisabeth Cardis; Antonis C Antoniou; Teresa Wagner; Jacques Simard; Gareth Evans; Susan Peock; Jean-Pierre Fricker; Catherine Nogues; Laura Van't Veer; Flora E Van Leeuwen; David E Goldgar Journal: J Clin Oncol Date: 2006-06-26 Impact factor: 44.544
Authors: Kathleen E Malone; Janet R Daling; David R Doody; Li Hsu; Leslie Bernstein; Ralph J Coates; Polly A Marchbanks; Michael S Simon; Jill A McDonald; Sandra A Norman; Brian L Strom; Ronald T Burkman; Giske Ursin; Dennis Deapen; Linda K Weiss; Suzanne Folger; Jennifer J Madeoy; Danielle M Friedrichsen; Nicola M Suter; Mariela C Humphrey; Robert Spirtas; Elaine A Ostrander Journal: Cancer Res Date: 2006-08-15 Impact factor: 12.701
Authors: Steven A Narod; Jan Lubinski; Parviz Ghadirian; Henry T Lynch; Pal Moller; William D Foulkes; Barry Rosen; Charmaine Kim-Sing; Claudine Isaacs; Susan Domchek; Susan Domcheck; Ping Sun Journal: Lancet Oncol Date: 2006-05 Impact factor: 41.316
Authors: Jeffrey N Weitzel; Mark Robson; Barbara Pasini; Siranoush Manoukian; Dominique Stoppa-Lyonnet; Henry T Lynch; Jane McLennan; William D Foulkes; Teresa Wagner; Nadine Tung; Parviz Ghadirian; Olufunmilayo Olopade; Claudine Isaacs; Charmaine Kim-Sing; Pal Møller; Susan L Neuhausen; Kelly Metcalfe; Ping Sun; Steven A Narod Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-06 Impact factor: 4.254
Authors: D K Gaffney; R M Brohet; C M Lewis; J A Holden; S S Buys; S L Neuhausen; L Steele; V Avizonis; J R Stewart; L A Cannon-Albright Journal: Radiother Oncol Date: 1998-05 Impact factor: 6.280
Authors: M P Little; M L Schaeffer; R C Reulen; D H Abramson; M Stovall; R Weathers; F de Vathaire; I Diallo; J M Seddon; M M Hawkins; M A Tucker; R A Kleinerman Journal: Br J Cancer Date: 2014-04-22 Impact factor: 7.640